Form 4: Teva Pharmaceutical Director Perry Nisen Reports Routine Equity Transactions

Teva Pharmaceutical Industries Ltd. Director Perry Nisen disclosed the vesting of previously granted restricted share units into ordinary shares and the grant of new restricted share units, aligning his interests with shareholders.

Summary

• Perry Nisen, a Director of Teva Pharmaceutical Industries Ltd. (TEVA), reported changes in his beneficial ownership of company securities.
• On June 6, 2025, 9,632 Restricted Share Units (RSUs) granted on June 6, 2024, vested and were converted into 9,632 Ordinary Shares.
• Following this transaction, Mr. Nisen's direct beneficial ownership of Ordinary Shares increased to 105,315.
• Additionally, on June 5, 2025, Mr. Nisen was granted 14,492 new Restricted Share Units, which are scheduled to vest on June 5, 2026.
• Each RSU represents a contingent right to receive one ordinary share or its cash equivalent at the option of the Human Resources and Compensation Committee.

Sentiment

Score: 7

Explanation: The document reports routine equity compensation transactions for a director, which is generally a neutral to slightly positive event as it indicates continued alignment of interests. There are no negative or unexpected elements.

Positives

• The grant of new Restricted Share Units to Director Perry Nisen indicates continued alignment of management's interests with those of shareholders.
• The vesting of previously granted RSUs demonstrates the execution of the company's equity compensation plan, providing long-term incentives for directors.

Future Outlook

The newly granted 14,492 Restricted Share Units are scheduled to vest on June 5, 2026, indicating future equity compensation for the director.

Industry Context

Form 4 filings are standard disclosures in the pharmaceutical industry, as in all public sectors, detailing changes in beneficial ownership by company insiders. These routine transactions reflect ongoing equity compensation practices aimed at aligning executive and director interests with long-term company performance.

Stakeholder Impact

• Shareholders: The equity compensation aligns the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The 14,492 Restricted Share Units granted on June 5, 2025, are expected to vest on June 5, 2026.

Key Dates

Keywords

Teva Pharmaceutical Industries, TEVA, Form 4, SEC filing, insider transaction, beneficial ownership, restricted share units, RSU, equity compensation, director, stock ownership